410 related articles for article (PubMed ID: 25972402)
1. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression.
Patel M; Carritt K; Lane J; Jayappa H; Stahl M; Bourgeois M
Clin Vaccine Immunol; 2015 Jul; 22(7):798-805. PubMed ID: 25972402
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge.
Stuke K; King V; Southwick K; Stoeva MI; Thomas A; Winkler MT
Vaccine; 2014 May; 32(22):2599-603. PubMed ID: 24662705
[TBL] [Abstract][Full Text] [Related]
3. Feline leukemia virus immunity induced by whole inactivated virus vaccination.
Torres AN; O'Halloran KP; Larson LJ; Schultz RD; Hoover EA
Vet Immunol Immunopathol; 2010 Mar; 134(1-2):122-31. PubMed ID: 20004483
[TBL] [Abstract][Full Text] [Related]
4. No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus.
Helfer-Hungerbuehler AK; Spiri AM; Riond B; Grest P; Boretti FS; Hofmann-Lehmann R
Vaccine; 2015 Mar; 33(13):1578-85. PubMed ID: 25698488
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a nonadjuvanted recombinant FeLV vaccine and two inactivated FeLV vaccines when subject to consistent virulent FeLV challenge conditions.
Grosenbaugh DA; Frances-Duvert V; Abedi S; Feilmeier B; Ru H; Poulet H
Biologicals; 2017 Sep; 49():76-80. PubMed ID: 28734742
[TBL] [Abstract][Full Text] [Related]
6. Protection against feline leukemia virus infection by use of an inactivated virus vaccine.
Hoover EA; Perigo NA; Quackenbush SL; Mathiason-DuBard CK; Overbaugh JM; Kloetzer WS; Elder JH; Mullins JI
J Am Vet Med Assoc; 1991 Nov; 199(10):1392-401. PubMed ID: 1666090
[TBL] [Abstract][Full Text] [Related]
7. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine.
Grosenbaugh DA; Leard T; Pardo MC
J Am Vet Med Assoc; 2006 Mar; 228(5):726-7. PubMed ID: 16506935
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of an inactivated feline leukemia virus vaccine.
Hoover EA; Mullins JI; Chu HJ; Wasmoen TL
AIDS Res Hum Retroviruses; 1996 Mar; 12(5):379-83. PubMed ID: 8882314
[TBL] [Abstract][Full Text] [Related]
9. Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunisation with Leukocell 2 vaccine.
Harbour DA; Gunn-Moore DA; Gruffydd-Jones TJ; Caney SM; Bradshaw J; Jarrett O; Wiseman A
Vaccine; 2002 Jul; 20(23-24):2866-72. PubMed ID: 12126896
[TBL] [Abstract][Full Text] [Related]
10. Protection against feline leukemia virus challenge for at least 2 years after vaccination with an inactivated feline leukemia virus vaccine.
Jirjis FF; Davis T; Lane J; Carritt K; Sweeney D; Williams J; Wasmoen T
Vet Ther; 2010; 11(2):E1-6. PubMed ID: 20957616
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study.
Lafrado LJ
J Am Vet Med Assoc; 1994 Mar; 204(6):914-7. PubMed ID: 8188511
[TBL] [Abstract][Full Text] [Related]
12. Recombinant feline leukemia virus (FeLV) variants establish a limited infection with altered cell tropism in specific-pathogen-free cats in the absence of FeLV subgroup A helper virus.
Bechtel MK; Hayes KA; Mathes LE; Pandey R; Stromberg PC; Roy-Burman P
Vet Pathol; 1999 Mar; 36(2):91-9. PubMed ID: 10098636
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines.
Poulet H; Thibault JC; Masias A
Clin Vaccine Immunol; 2015 Dec; 22(12):1294-5. PubMed ID: 26604264
[No Abstract] [Full Text] [Related]
14. Reply to "Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines".
Patel M; Carritt K; Lane J; Jayappa H; Stahl M; Bourgeois M
Clin Vaccine Immunol; 2015 Dec; 22(12):1296-7. PubMed ID: 26604265
[No Abstract] [Full Text] [Related]
15. Immunization with the transmembrane protein of a retrovirus, feline leukemia virus: absence of antigenemia following challenge.
Langhammer S; Hübner J; Jarrett O; Kurth R; Denner J
Antiviral Res; 2011 Jan; 89(1):119-23. PubMed ID: 21108970
[TBL] [Abstract][Full Text] [Related]
16. Real-time PCR investigation of feline leukemia virus proviral and viral RNA loads in leukocyte subsets.
Cattori V; Pepin AC; Tandon R; Riond B; Meli ML; Willi B; Lutz H; Hofmann-Lehmann R
Vet Immunol Immunopathol; 2008 May; 123(1-2):124-8. PubMed ID: 18304650
[TBL] [Abstract][Full Text] [Related]
17. Development and testing of an inactivated feline leukemia virus vaccine.
Hoover EA; Mullins JI; Chu HJ; Wasmoen TL
Semin Vet Med Surg Small Anim; 1995 Nov; 10(4):238-43. PubMed ID: 8820598
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously.
Grosenbaugh DA; Leard T; Pardo MC; Motes-Kreimeyer L; Royston M
Vet Ther; 2004; 5(4):258-62. PubMed ID: 15719325
[TBL] [Abstract][Full Text] [Related]
19. Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up.
Hofmann-Lehmann R; Cattori V; Tandon R; Boretti FS; Meli ML; Riond B; Pepin AC; Willi B; Ossent P; Lutz H
Vaccine; 2007 Jul; 25(30):5531-9. PubMed ID: 17240486
[TBL] [Abstract][Full Text] [Related]
20. Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays.
Hofmann-Lehmann R; Tandon R; Boretti FS; Meli ML; Willi B; Cattori V; Gomes-Keller MA; Ossent P; Golder MC; Flynn JN; Lutz H
Vaccine; 2006 Feb; 24(8):1087-94. PubMed ID: 16198454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
